Yujiro Suzuki

发表

Superior cross‐protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine

T. Kurata, S. Tamura, H. Asanuma, 1992, European journal of immunology.

Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.

A. Nomoto, T. Kurata, S. Tamura, 2002, Vaccine.

Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia.

N. Kondo, T. Sata, Yuko Sato, 2003, Vaccine.

Secretory IgA antibodies provide cross‐protection against infection with different strains of influenza B virus

Y. Iwakura, T. Sata, T. Kurata, 2004, Journal of medical virology.

Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.

Y. Fujita-Yamaguchi, T. Sata, T. Kurata, 2007, Vaccine.

Protection Against Influenza Virus Infection in Polymeric Ig Receptor Knockout Mice Immunized Intranasally with Adjuvant-Combined Vaccines

Y. Iwakura, Yuko Sato, H. Hasegawa, 2002, The Journal of Immunology.

Adjuvant-Combined Vaccines Immunized Intranasally with in Polymeric Ig Receptor Knockout Mice Protection Against Influenza Virus Infection

Y. Iwakura, Yuko Sato, H. Hasegawa, 2002 .

Influenza PR8 HA-specific Fab fragments produced by phage display methods.

M. Matsushita, T. Sata, S. Tamura, 2008, Biochemical and biophysical research communications.

Total viral genome copies and virus-Ig complexes after infection with influenza virus in the nasal secretions of immunized mice.

A. Nomoto, T. Sata, T. Kurata, 2004, The Journal of general virology.

Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant

T. Ichinohe, Hidehiro Takahashi, H. Sawa, 2006, Journal of medical virology.

Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.

T. Nagamine, T. Kurata, S. Tamura, 1996, Vaccine.

Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.

T. Nagamine, K. Komase, T. Kurata, 1994, Vaccine.

Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine.

K. Komase, T. Kurata, S. Tamura, 1998, Vaccine.

Comparison of substrate specificities of sialidase activity between purified enzymes from influenza virus A (H1N1 and H3N2 subtypes) and B strains and their original viruses.

H. Yamada, Yujiro Suzuki, T. Nagai, 1995, Biological & pharmaceutical bulletin.

Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria-pertussis-tetanus vaccines.

T. Nagamine, S. Tamura, Y. Suzuki, 2001, Vaccine.

Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine.

T. Sata, T. Kurata, S. Tamura, 2001, Vaccine.

Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration.

T. Nagamine, T. Kurata, S. Tamura, 1995, Vaccine.

Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.

Hidehiro Takahashi, T. Iwasaki, T. Kurata, 1999, Vaccine.